[交流] NDA for tasocitinib to treat RA 已有5人参与

Pfizer Inc. (NYSEFE), New York, N.Y. Product: Tofacitinib (CP-690,550) (formerly tasocitinib) Business: Autoimmune Molecular target: Janus kinase-3 (JAK-3); Janus kinase-1 (JAK-1) Description: Oral pan-Janus kinase (JAK) inhibitor An NDA for tofacitinib to treat rheumatoid arthritis (RA) is under FDA review with an Aug. 21 PDUFA date, while an MAA is under review in the EU. The product is also under review in Japan. In a conference call to discuss its 2Q12 earnings, Pfizer said FDA requested additional analysis of data in the NDA for tofacitinib, which the pharma said could cause the agency to extend its review of the product past its PDUFA date. Specifics about the request were not disclosed (see BioCentury, Aug. 6). Tofacitinib also is in Phase III testing to treat moderate to severe plaque psoriasis. Takeda Pharmaceutical Co. Ltd. (Tokyo:4502, Osaka, Japan) has rights from Pfizer to co-market tofacitinib in Japan for RA and other undisclosed indications

回复此楼

» 收录本帖的淘帖专辑推荐

新药发现

» 猜你喜欢

• 药物学论文润色/翻译怎么收费? 已经有69人回复

高级回复

» 本主题相关价值贴推荐，对您同样有帮助:

• 香港RA签注办理咨询 已经有17人回复
• International Journal for Numerical Methods in Engineering二审时间 已经有13人回复
• 拿到了美国一个大学的OFFER，但是外导给的RA补助不够生活费 已经有8人回复
• 求苯的分子轨道能级（molecular orbital binding energies for benzene） 已经有8人回复
• 【the song I want to sing for u】My love by 小猫（重在参与）O(∩_∩)O~ 已经有94人回复
• 首届【唱我最想唱的外语歌曲】xxx(the song I want to sing for u)比赛 已经有141人回复
• Fortran中关于数组的变化 已经有5人回复
• 新威电池测试仪怎么从NDA文件中导出EXCEL文件？ 已经有4人回复
• 【求助】内地博士没毕业，可以申请理大的RA吗？ 已经有10人回复